Literature DB >> 19735581

Cytokines in the colon of a patient with Behçet's disease.

Jasper H Kappen, Willem A Dik, Gemma M Dingjan, Paul L van Daele, Herbert Hooijkaas, P Martin van Hagen, Jan A van Laar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735581      PMCID: PMC2745804          DOI: 10.1186/ar2784

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


× No keyword cloud information.

We read with interest the article by Cañete and colleagues [1] in a recent issue of Arthritis Research & Therapy, in which they describe cytokine patterns of inflamed joints from patients with Behçet's disease (BD). The authors show that neutrophils and T lymphocytes are involved in a Th1-skewed inflammatory pattern expressed by elevations of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2). Also, increased levels of IL-4, IL-10, and IL-17 were observed. We would like to add to these observations our data showing a similar cytokine profile in the colon of a patient with BD. A 37-year-old BD patient with severe colitis failed to respond to traditional immunosuppressive treatment. Steroids were contraindicated because of a previous retinal serosal ablation, probably induced by prednisone. TNF blockage initially successfully reduced the severity of the colitis, but relapses occurred. Variation of different TNF blockers (etanercept, infliximab, and adalimumab) could not permanently resolve the intestinal complaints. Antibodies against infliximab or adalimumab were not detected. Eventually, high-dose infliximab (10 mg/kg) and intravenous immunoglobulins (IVIGs) led to disease regression facilitating a hemicolectomy. Thereafter, the patient's condition improved significantly and IVIGs were terminated while TNF blockage was continued. Cytokines were evaluated in the resected colon by analyzing mRNA expression levels of cytokine genes as previously described [2]. Because of the extensive prior treatment, the patient served as an internal control. Intestinal inflammation was patchy, and the observed difference between healthy and diseased tissues was confirmed microscopically. The mRNA expression of cytokines in diseased colon is presented relative to that of healthy colon and can be seen as a reflection of intramural cytokines (Figure 1). Like Cañete and colleagues, we observed a Th1- and Th17-skewed pattern (elevated IFN-γ and TNF-α and elevated IL-17A, respectively). We could not demonstrate elevation of IL-10, possibly because our patient was intensively treated and the colon environment is not sterile.
Figure 1

Relative mRNA expression of cytokine genes in affected colonic tissue of a patient with Behçet's disease. Diseased colonic tissue and healthy colonic tissue from the same patient were analyzed. IFN-γ, interferon-gamma; IL, interleukin; TNF, tumor necrosis factor.

Relative mRNA expression of cytokine genes in affected colonic tissue of a patient with Behçet's disease. Diseased colonic tissue and healthy colonic tissue from the same patient were analyzed. IFN-γ, interferon-gamma; IL, interleukin; TNF, tumor necrosis factor. The immunopathology of BD remains fascinating and highly relevant to the development of future immune-directed therapy. Since the successful introduction of TNF blockers, it became apparent that Th1-cytokines might be key players in the immunopathology of BD, emphasizing the importance of cytokine studies [3,4]. Cañete and colleagues [1] have highlighted the importance of tissue evaluation in cytokine studies. In this light, our data add to their observations that, in colonic tissue of a BD patient, IFN-γ, TNF-α, and IL-17A appear to be key cytokines, even in a treated patient.

Abbreviations

BD: Behçet's disease; IFN-γ: interferon-gamma; IL: interleukin; IVIG: intravenous immunoglobulin; TNF: tumor necrosis factor.

Competing interests

The authors declare that they have no competing interests.
  4 in total

1.  Adalimumab: a new modality for Behçet's disease?

Authors:  J A M van Laar; T Missotten; P L A van Daele; A Jamnitski; G S Baarsma; P M van Hagen
Journal:  Ann Rheum Dis       Date:  2006-11-23       Impact factor: 19.103

Review 2.  Behçet's syndrome: disease manifestations, management, and advances in treatment.

Authors:  Hasan Yazici; Izzet Fresko; Sebahattin Yurdakul
Journal:  Nat Clin Pract Rheumatol       Date:  2007-03

3.  Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL.

Authors:  Willem A Dik; Bertrand Nadel; Grzegorz K Przybylski; Vahid Asnafi; Piotr Grabarczyk; Jean Marc Navarro; Brenda Verhaaf; Christian A Schmidt; Elizabeth A Macintyre; Jacques J M van Dongen; Anton W Langerak
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

4.  Distinct synovial immunopathology in Behçet disease and psoriatic arthritis.

Authors:  Juan D Cañete; Raquel Celis; Troy Noordenbos; Conchita Moll; Jose A Gómez-Puerta; Pilar Pizcueta; Antonio Palacin; Paul P Tak; Raimon Sanmartí; Dominique Baeten
Journal:  Arthritis Res Ther       Date:  2009-02-06       Impact factor: 5.156

  4 in total
  3 in total

1.  Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet's Disease: Eight Consecutive Cases.

Authors:  Satoshi Tanida; Tsutomu Mizoshita; Hirotada Nishie; Keiji Ozeki; Takahito Katano; Takaya Shimura; Eiji Kubota; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh
Journal:  J Clin Med Res       Date:  2016-02-27

Review 2.  Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.

Authors:  Jihye Park; Jae Hee Cheon
Journal:  Gut Liver       Date:  2018-11-15       Impact factor: 4.519

3.  Behҫet's Disease, and the Role of TNF-α and TNF-α Blockers.

Authors:  Tim van der Houwen; Jan van Laar
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.